Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.
- DOI
- 10.1016/s1470-2045(26)00144-0
- Published
- 2026 Aug
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-26-00144-0,
title = {Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.},
author = {Quik JSE and Vollebergh MA and Retèl VP and van der Sluis K and Koemans WJ and van der Kaaij RT and Voets MM and Luyer MDP and van Hellemond IEG and Wijnhoven BPL and Mostert B and van Hillegersberg R and Mohammad NH and van Etten B and de Groot DJ and Helminen O and Hedberg J and Cashin PH and Harbjerg JL and Veenhof AAFA and Hartemink KJ and Kodach LL and van der Noort V and van Sandick JW and PERISCOPE II consortium},
year = {2026},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(26)00144-0},
url = {https://doi.org/10.1016/s1470-2045(26)00144-0}
}RIS
TY - JOUR TI - Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis. AU - Quik JSE AU - Vollebergh MA AU - Retèl VP AU - van der Sluis K AU - Koemans WJ AU - van der Kaaij RT AU - Voets MM AU - Luyer MDP AU - van Hellemond IEG AU - Wijnhoven BPL AU - Mostert B AU - van Hillegersberg R AU - Mohammad NH AU - van Etten B AU - de Groot DJ AU - Helminen O AU - Hedberg J AU - Cashin PH AU - Harbjerg JL AU - Veenhof AAFA AU - Hartemink KJ AU - Kodach LL AU - van der Noort V AU - van Sandick JW AU - PERISCOPE II consortium PY - 2026 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(26)00144-0 UR - https://doi.org/10.1016/s1470-2045(26)00144-0 ER -
APA
JSE, Q., MA, V., VP, R., K, V. D. S., WJ, K., RT, V. D. K., MM, V., MDP, L., IEG, V. H., BPL, W., B, M., R, V. H., NH, M., B, V. E., DJ, D. G., O, H., J, H., PH, C., JL, H., AAFA, V., KJ, H., LL, K., V, V. D. N., JW, V. S., & consortium, P. I. (2026). Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00144-0
Source records
- pubmed · retrieved 2026-09-27T01:35:53.787Z